Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
Background: Clinical efficacy of zilucoplan has been demonstrated in a 12-week, placebo-controlled, phase III study in patients with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG). However, placebo-controlled zilucoplan data past 12 weeks are not available. Objectiv...
| Hlavní autoři: | , , , , , , , , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
SAGE Publishing
2024-09-01
|
| Edice: | Therapeutic Advances in Neurological Disorders |
| On-line přístup: | https://doi.org/10.1177/17562864241279125 |